Insmed Incorporated (INSM) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 3[1], 3 Phase 2[2].
Trial NCT05649722[4] evaluates Treprostinil Palmitil Inhalation Powder in Pulmonary Hypertension with a target enrollment of 31 participants. Trial NCT07179380[5] evaluates Treprostinil Palmitil Inhalation Powder in Pulmonary Hypertension with a target enrollment of 344 participants. Trial NCT05649748[6] evaluates Treprostinil Palmitil in Pulmonary Arterial Hypertension with a target enrollment of 91 participants.
INSM has 4 Form 4 insider filings recorded at the SEC in the past 30 days[7].